FENC Latest Headlines

Buy Rating on Fennec Pharmaceuticals Driven by PEDMARK’s Long-Term Adoption Potential, Emerging Japan Upside, and Improving Profitability Supporting a $13 Target

at www.tipranks.com (Thu, 5-Mar 6:25 AM)

Fennec, Tampa General launch real-world PEDMARK oncology study

at www.tipranks.com (Wed, 4-Mar 5:13 PM)

Analysts Offer Insights on Healthcare Companies: Cerus (CERS) and Fennec Pharmaceuticals (FENC)

at www.tipranks.com (Wed, 4-Mar 10:30 AM)